An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT06589596
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $734,261
- U.S. investigators named
- 6
- Sites paid
- 7
- Planned or actual enrollment
- 695
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-58067 (drug), BG-89894 (drug), Standard of Care Therapy (drug), RAS(ON) Inhibitors (drug)
- Dates
- Started 2025-01-10; completion 2028-08-31
- Results posted
- Not yet
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), in combination with standard of care therapy, and in combination with novel anticancer therapies in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $734,261 in research payments for this study in 2025 (50 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jacob S. Thomas Medical Oncology · Los Angeles, CA
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Ugonma N. Chukwueke, M.D. Neurology · Boston, MA
- Jordi Rodon, MD Medical Oncology · Houston, TX
- Michael Song, MD Hematology & Oncology · San Antonio, TX
- Mohamad A. Salkeni, M.D. Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $179,086
- Dana Farber Mass General Brigham Cancer Care Inc $150,399
- Ut MD Anderson Cancer Center $120,980
- University of Southern California, Norris Comprehensive Cancer Center $109,984
- Adventhealth Orlando, FL $76,177
- Next Oncology $63,580
- Next Virginia, LLC $34,055
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.